SCYNEXIS Investor Relations Material
Latest events
Q4 2022 & Business Update
SCYNEXIS
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from SCYNEXIS Inc
Access all reports
SCYNEXIS Inc. is a biotechnology company focused on the research, development, and commercialization of innovative therapies for fungal infections. The company's lead product, based on a novel antifungal platform, is designed to address severe and drug-resistant fungal infections in both hospital and outpatient settings. SCYNEXIS develops treatments for conditions with significant unmet medical needs, with a particular emphasis on antifungal agents targeting life-threatening infections. The company is headquartered in Jersey City, USA, and its shares are listed on the NASDAQ.
Latest articles
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
)
Intuitive Surgical: Enhancing Surgery with Robotic Precision
Intuitive Surgical has revolutionized surgery with robotics, building its dominant position through decades of innovation, validation, and expansion.
2 May 2025
Ticker symbol
SCYX
Country
🇺🇸 United States